Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JMS CoTSE:7702 +0.44%60 Debt-to-Equity is 0.67 as of Mar. 2026, which is 14% above its 10-year median of 0.59. GuruFocus rates TSE:7702 with a GF Score™ of 60/100 and a GF Value™ of 円509.07 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 698 Medical Devices & Instruments companies, JMS Co ranks worse than 75.36% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for JMS Co's Debt-to-Equity or its related term are showing as below:
TSE:7702'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.51 Med: 0.59 Max: 0.67
Current: 0.63
During the past 13 years, the highest Debt-to-Equity Ratio of JMS Co was 0.67. The lowest was 0.51. And the median was 0.59.
TSE:7702's Debt-to-Equity is ranked worse than 75.36% of 698
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs TSE:7702: 0.63
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
JMS Co Debt-to-Equity Related Terms
JMS Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for JMS Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7702 vs ISRG, BDX, RMD: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, JMS Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JMS Co Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, JMS Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where JMS Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JMS Co (TSE:7702) has a Debt-to-Equity of 0.67 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on JMS Co and its competitors. This is 14% above median its historical median of 0.59. Over the past decade, JMS Co's Debt-to-Equity has ranged from 0.51 to 0.67. According to the industry distribution chart, JMS Co ranks #526 out of 698 companies in the Medical Devices & Instruments industry, placing it in the top 75.4%.
Is JMS Co's Debt-to-Equity too high?
JMS Co's current Debt-to-Equity of 0.67 is 14% above median its 10-year median of 0.59. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 0.67. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. JMS Co's value of 0.67 is 179.2% above this industry median. Based on the distribution chart, JMS Co ranks #526 out of 698 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, JMS Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JMS Co's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, JMS Co ranks #526 out of 698 companies for Debt-to-Equity. This places JMS Co in the lower half of its industry. The industry median Debt-to-Equity is 0.24. JMS Co's value of 0.67 is 179.2% above this benchmark. Historically, JMS Co's own Debt-to-Equity has ranged from 0.51 to 0.67 over the past decade. While the company's 10-year median is 0.59 vs. the industry median of 0.24, JMS Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JMS Co's current Debt-to-Equity of 0.67 is 179.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on JMS Co and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JMS Co's current Debt-to-Equity is 0.67, which is 14% above median its own 10-year median of 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JMS Co stock overvalued right now?
Based on GuruFocus' analysis, JMS Co (TSE:7702) is currently considered Modestly Undervalued. The stock's GF Value™ is 円509.07, compared to a current price of 円453.00 — trading 11% below its estimated fair value. The current Debt-to-Equity is 0.67, which is 14% above median its 10-year median of 0.59 and 179.2% above the Medical Devices & Instruments industry median of 0.24. JMS Co's overall GF Score™ is 60/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For JMS Co (TSE:7702), the current Debt-to-Equity is 0.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JMS Co (TSE:7702) Overvalued in 2026?
Based on GuruFocus' analysis, JMS Co stock appears to be undervalued.
The current stock price of 円453.00 is trading 11% below its estimated GF Value™ of 円509.07.
GuruFocus considers JMS Co to be Modestly Undervalued.
Key valuation signals for TSE:7702:
Debt-to-Equity: 0.67 (14% above median its 10-year median of 0.59)
GF Value™: 円509.07 vs. price of 円453.00 (11% below fair value)
Industry Position: 179.2% above the Medical Devices & Instruments median (#526 of 698)
No single metric tells the full story. See the TSE:7702 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JMS Co Ltd is a Japan-based medical equipment manufacturer. The company is engaged in the manufacture, sale, export, and import of medical equipment and pharmaceuticals. Products offered by the company include an infusion pump, syringe pump, surgical gown, peritoneal dialysate, dialyzer, mask cap, sheet for treatment, pacemaker, heat exchanger, blood bag, among others. JMS has network operations in various countries including Europe, North America, Asia, the Middle East, Latin America and Africa.
60GF Score
Get the complete analysis for TSE:7702
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7702 has been successfully added to your 
